malondialdehyde has been researched along with fluorobenzenes in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Budinsky, A; Resch, U; Sinzinger, H; Tatzber, F | 1 |
| Ansimova, OM; Chalyk, NE; Dovgalevskiĭ, PIa; Il'in, AA; Klochkov, VA; Petyaev, I | 1 |
| Arslan, S; Güler, A; Kılıçkaya, O; Onan, B; Oztaş, E; Sahin, MA; Ucak, A; Uysal, B; Yılmaz, AT | 1 |
| Catoi, C; Clichici, S; Dudea, M; Filip, A; Mircea, PA; Muresan, A; Nagy, A; Olteanu, D | 1 |
| Chen, C; Dai, R; Lin, R; Su, Z; Wu, B; Wu, H | 1 |
| Aloe, A; Carresi, C; Gliozzi, M; Gratteri, S; Janda, E; Mollace, V; Muscoli, C; Muscoli, S; Musolino, V; Palma, E; Ragusa, S; Romeo, F; Russo, V; Vitale, C; Walker, R | 1 |
| Jiang, F; Li, R; Sun, L; Yang, J; Zhang, L; Zhao, Q; Zhuo, L | 1 |
| Frölich, JC; Maassen, N; Modun, D; Rothmann, S; Schneider, JY; Stuke, N; Suchy, MT; Trettin, A; Tsikas, D | 1 |
3 trial(s) available for malondialdehyde and fluorobenzenes
| Article | Year |
|---|---|
Reduction of oxidative stress and modulation of autoantibodies against modified low-density lipoprotein after rosuvastatin therapy.
Topics: Antioxidants; Autoantibodies; Biomarkers; Copper; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoglobulin G; Immunoglobulin M; Lipoproteins, LDL; Male; Malondialdehyde; Middle Aged; Oxidation-Reduction; Oxidative Stress; Peroxidase; Peroxides; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2006 |
Bergamot polyphenolic fraction enhances rosuvastatin-induced effect on LDL-cholesterol, LOX-1 expression and protein kinase B phosphorylation in patients with hyperlipidemia.
Topics: beta-Cyclodextrins; Cholesterol, LDL; Citrus; Drug Synergism; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipid Peroxidation; Male; Malondialdehyde; Phosphorylation; Placebos; Plant Extracts; Prospective Studies; Proto-Oncogene Proteins c-akt; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Scavenger Receptors, Class E; Sulfonamides; Triglycerides | 2013 |
Rosuvastatin reduces ischemia-reperfusion injury in patients with acute coronary syndrome treated with percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Biomarkers; China; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Malondialdehyde; Middle Aged; Myocardial Reperfusion Injury; Natriuretic Peptide, Brain; Percutaneous Coronary Intervention; Pyrimidines; Rosuvastatin Calcium; Stroke Volume; Sulfonamides; Superoxide Dismutase; Time Factors; Treatment Outcome; Ventricular Function, Left | 2014 |
5 other study(ies) available for malondialdehyde and fluorobenzenes
| Article | Year |
|---|---|
[Significance of determination of lipid-oxidizing catalytic antibodies in patients with ischemic heart diseases].
Topics: Aged; Antibodies, Catalytic; Antigens, Bacterial; Antioxidants; Carotenoids; Chlamydophila pneumoniae; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Lipid Peroxidation; Lycopene; Male; Malondialdehyde; Middle Aged; Myocardial Ischemia; Oxidation-Reduction; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2009 |
Rosuvastatin, a new generation 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, reduces ischemia/reperfusion-induced spinal cord tissue injury in rats.
Topics: Analysis of Variance; Animals; Aorta, Abdominal; Cytoprotection; Disease Models, Animal; Fluorobenzenes; Glutathione Peroxidase; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Malondialdehyde; Motor Activity; Necrosis; Neurologic Examination; Neuroprotective Agents; Pyrimidines; Rats; Rats, Wistar; Reperfusion Injury; Rosuvastatin Calcium; Spinal Cord; Spinal Cord Injuries; Sulfonamides; Superoxide Dismutase; Time Factors | 2011 |
Hepatic and systemic effects of rosuvastatin on an experimental model of bile duct ligation in rats.
Topics: Actins; Alanine Transaminase; Animals; Aspartate Aminotransferases; Bile Ducts; Brain; Cholestasis; Disease Models, Animal; Female; Fluorobenzenes; gamma-Glutamyltransferase; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Ligation; Liver; Malondialdehyde; NF-kappa B; Oxidative Stress; Proliferating Cell Nuclear Antigen; Protein Carbonylation; Pyrimidines; Rats; Rats, Wistar; Receptors, Tumor Necrosis Factor, Type II; Rosuvastatin Calcium; Sulfonamides; Transforming Growth Factor beta1 | 2012 |
Short-time pretreatment of rosuvastatin attenuates myocardial ischemia and reperfusion injury by inhibiting high mobility group box 1 protein expression.
Topics: Animals; Biomarkers; Fluorobenzenes; HMGB1 Protein; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Malondialdehyde; Myocardial Ischemia; Oxidative Stress; Premedication; Pyrimidines; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Rosuvastatin Calcium; Sulfonamides; Superoxide Dismutase | 2013 |
Development, validation and biomedical applications of stable-isotope dilution GC-MS and GC-MS/MS techniques for circulating malondialdehyde (MDA) after pentafluorobenzyl bromide derivatization: MDA as a biomarker of oxidative stress and its relation to 1
Topics: Biomarkers; Deuterium; Dinoprost; Fluorobenzenes; Gas Chromatography-Mass Spectrometry; Humans; Indicator Dilution Techniques; Malondialdehyde; Nitric Oxide; Oxidative Stress; Tandem Mass Spectrometry | 2016 |